Home/Magenta Therapeutics/Michael D. Clayman
MD

Michael D. Clayman

Former Chairman of the Board

Magenta Therapeutics

Magenta Therapeutics Pipeline

DrugIndicationPhase
MGTA-117Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) (Conditioning)Phase 1/2
MGTA-145Multiple Myeloma / Lymphoma (Stem Cell Mobilization)Phase 2
MGTA-45Acute Leukemias (Conditioning)Preclinical
CD38-ADCAutoimmune Diseases (e.g., Lupus) (Conditioning)Discovery